dose-response efficacy proprietary probiotic formula lactobacillus acidophilus cl num lactobacillus casei lbc num antibiotic-associa pubmed ncbi abstract objectives standard therapies antibiotic-associated diarrhea aad clostridium difficile-associated diarrhea cdad limited efficacy probiotic prophylaxis promising alternative reduction aad cdad incidence methods single-center randomized double-blind placebo-controlled dose-ranging study randomized num adult inpatients groups probiotic capsules day pro num num probiotic capsule placebo capsule day pro num num placebo capsules day num probiotic capsule contained num billion c f u live organisms lactobacillus acidophilus cl num lactobacillus casei lbc num bio-k cl num probiotic prophylaxis began num initial antibiotic administration continued num days antibiotic dose patients additional num days results pro num num lower aad incidence pro num num probiotic group lower aad incidence placebo num patients acquired aad pro num num days pro num num days shorter symptom duration placebo num days similarly pro num num lower cdad incidence pro num num treatment group lower cdad incidence placebo num gastrointestinal symptoms common treatment groups placebo pro num pro num conclusions proprietary probiotic blend study tolerated effective reducing risk aad cdad hospitalized patients antibiotics dose-ranging effect shown num billion c f u yielding superior outcomes fewer gastrointestinal events compared num billion c f u clinicaltrials gov number nct num 
